Short answer
CRISPR Therapeutics AG (CRSP) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $10M (up 1041.4% year over year) with net income of −$91M.
Q2 2026 key financials · XBRL
- Revenue
- $10M
- +1041.4% YoY · +598.3% QoQ
- Net income
- −$91M
- +56.3% YoY · +25.8% QoQ
- Operating margin
- -1151.8%
- EPS (diluted)
- −$0.94
- +60.8% YoY · +26.6% QoQ
Source: XBRL data from the CRISPR Therapeutics AG (CRSP) Q2 2026 10-Q on SEC EDGAR. USD.
CRISPR Therapeutics AG Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $10.181M, up $9.289M YoY from $892K
- Net loss $91.154M vs $208.549M YoY
- Operating loss $117.269M vs $229.324M YoY
- Operating expenses $127.450M, down $102.766M YoY
- Collaboration revenue $10.0M from license upfront payment; no comparable 2025 revenue
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 and signatures only
- New executive trading plans through May 31, 2027, covering 93,632 and 14,565 common shares
- New 2026 Stock Option and Incentive Plan, filed June 4, 2026, creating potential equity-compensation dilution
- No regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed in the provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CRISPR Therapeutics AG quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.